Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma

Cancer

Volumn 83, Issue 3, 1998, Pages 490-497

  Heslin, Martin J ^a,b   Cordon Cardo, Carlos ^a   Lewis, Jonathan J ^a   Woodruff, James M ^a   Brennan, Murray F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cell cycle; Ki 67; mdm2; MIB 1; p53; Preoperarive evaluation; Rb; Soft tissue sarcoma

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LIMB TUMOR; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; EXTREMITIES; FEMALE; GENES, RETINOBLASTOMA; HUMANS; IMMUNOPHENOTYPING; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SARCOMA;

EID: 0032147112     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980801)83:3<490::AID-CNCR18>3.0.CO;2-R     Document Type: Article

References (33)

1. Cordon-Cardo C. Mutations of cell cycle regulators: biological and clinical implications for human neoplasia. Am J Pathol 1995;147:545-60.
2. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
3. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
4. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
5. Defeo-Jones D, Huang PS, Jones RE, Haskell KM, Vuocolo GA, Hanobik MG, et al. Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product. Nature 1991;352:251-4.
6. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
7. Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1990;1:199-206.
8. Cance WG, Brennan MF, Dudas ME, Huang CM, Cordon-Cardo C. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 1990;323:1457-62.
9. Karpeh MS, Brennan MF, Cance WG, Woodruff JM, Pollack D, Casper ES, et al. Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Br J Cancer 1995;72:986-91.
10. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-9.
11. Wadayama B, Toguchida J, Yamaguchi T, Sasaki MS, Yamamuro T. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 1993;68:1134-9.
12. Kawai A, Noguchi M, Beppu Y, Yokoyama R, Mukai K, Hirohashi S, et al. Nuclear immunoreaction of p53 protein in soft tissue sarcomas: a possible prognostic factor. Cancer 1994;73:2499-505.
13. Drobnjak M, Latres E, Pollack D, Karpeh M, Dudas M, Woodruff JM, et al. Prognostic implications of p53 nuclear over-expression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst 1994;86:549-54.
14. Latres E, Drobnjak M, Pollack D, Oliva MR, Ramos M, Karpeh M, et al. Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am J Pathol 1994; 145:345-55.
15. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993;53(Suppl):2231-4.
16. Andreassen A, Oyjord T, Hovig E, Holm R, Florenes VA, Nesland JM, et al. p53 abnormalities in different subtypes of human sarcomas. Cancer Res 1993;53:468-71.
17. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
18. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993;53:16-8.
19. Nakayama T, Toguchida J, Wadayama B, Kanoe H, Kotoura Y, Sasaki MS, MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Int J Cancer 1995;64: 342-6.
20. Choong PF, Akerman M, Willen H, Andersson C, Gustafson P, Alvegard T, et al. Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in soft tissue sarcoma: is prognostic significance histotype-specific? APMIS 1995;103:797-805.
21. Choong PF, Akerman M, Willen H, Andersson C, Gustafson P, Baldetorp B, et al. Prognostic value of Ki-67 expression in 182 soft tissue sarcomas. Proliferation - a marker of metastasis? APMIS 1994;102:915-24.
22. Hajdu SI, Shiu MH, Brennan MF. The role of the pathologist in the management of soft tissue sarcomas. World J Surg 1988;12:326-31.
23. Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996;14:859-68.
24. Gaynor JJ, Tan CC, Casper ES, Collin CF, Friedrich C, Shiu M, et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 1992;10:1317-29.
25. Cox DR. Regression models and life tables. J R Stat Assoc B 1972;34:187-220.
26. SPSS for Windows. Version 7.0. Chicago, IL: SPSS, 1995.
27. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Part I. Cancer Chemother Rep 1966;50:163-70.
28. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;8:423-46.
29. Heslin MJ, Woodruff J, Brennan MF. Prognostic significance of a positive microscopic margin in high-risk extremity soft tissue sarcoma: implications for management. J Clin Oncol 1996;14:473-8.
30. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14:1679-89.
31. Heslin MJ, Lewis JJ, Woodruff JM, Brennan MF. Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol. In press.
32. Reich NC, Oren M, Levine AJ. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol 1983;3:2143-50.
33. Abramson DH, Ellsworth RM, Kitchin FD, Tung G. Second nonocular tumors in retinoblastoma survivors: are they radiation-indueuced Ophthalmology 1984;91:1351-5.